Showing results (11-20 of 21) with videos related to
Sort By:
Pageof 3
Immunology and Cell Biology|September 7, 2011
ISCOMATRIX vaccines mediate CD8+ T-cell cross-priming by a MyD88-dependent signaling pathwayNicholas S Wilson, Becky Yang, Adriana Baz Morelli, et al.Elife|September 21, 2018
UBE2G1 governs the destruction of cereblon neomorphic substratesGang Lu, Stephanie Weng, Mary Matyskiela, et al.Blood|April 15, 2015
Clinical and pharmacodynamic analysis of pomalidomide dosing strategies in myeloma: impact of immune activation and cereblon targetsKartik Sehgal, Rituparna Das, Lin Zhang, et al.Blood|January 25, 2020
Leveraging gene expression subgroups to classify DLBCL patients and select for clinical benefit from a novel agentAlberto Risueño, Patrick R Hagner, Fadi Towfic, et al.The Lancet. Haematology|February 22, 2017
Lenalidomide maintenance in patients with relapsed diffuse large B-cell lymphoma who are not eligible for autologous stem cell transplantation: an open label, single-arm, multicentre phase 2 trialAndrés J M Ferreri, Marianna Sassone, Francesco Zaja, et al.Nature Chemical Biology|September 8, 2018
SALL4 mediates teratogenicity as a thalidomide-dependent cereblon substrateMary E Matyskiela, Suzana Couto, Xinde Zheng, et al.Plos One|March 12, 2020
Targeting the Wnt signaling pathway through R-spondin 3 identifies an anti-fibrosis treatment strategy for multiple organsMingjun Zhang, Michael Haughey, Nai-Yu Wang, et al.Leukemia & Lymphoma|August 20, 2020
A phase II study of pomalidomide, daily oral cyclophosphamide, and dexamethasone in relapsed/refractory multiple myelomaOliver Van Oekelen, Samir Parekh, Hearn J Cho, et al.Blood|May 24, 2015
CC-122, a pleiotropic pathway modifier, mimics an interferon response and has antitumor activity in DLBCLPatrick R Hagner, Hon-Wah Man, Celia Fontanillo, et al.Blood|January 25, 2020
Avadomide monotherapy in relapsed/refractory DLBCL: safety, efficacy, and a predictive gene classifierCecilia Carpio, Reda Bouabdallah, Loïc Ysebaert, et al.Pageof 3